Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.700 -0.030 (-1.10%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2026 Add to My Watchlist

Price and Volume

Volume	270,983
Open	2.740
Bid (Size)	2.680 (100)
Ask (Size)	2.700 (600)
Prev. Close	2.730
Today's Range	2.690 - 2.825
52wk Range	1.150 - 3.600
Shares Outstanding	40,501,258
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

July 07, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

June 16, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+33.7%	+33.7%
1 Month	+24.4%	+24.4%
3 Month	+4.7%	+4.7%
6 Month	+35.7%	+35.7%
1 Year	+123.1%	+123.1%

More News

Acumen (ABOS) Q1 2026 Earnings Transcript ↗

May 12, 2026

Via The Motley Fool

Acumen Pharmaceuticals (NASDAQ:ABOS) Q1 2026 Loss Narrows as Phase 2 Alzheimer's Trial Readout Looms ↗

May 12, 2026

Via Chartmill

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update ↗

March 26, 2026

Via Chartmill

Acumen Pharmaceuticals Q1 Earnings Call Highlights ↗

May 12, 2026

Via MarketBeat

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

May 12, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

May 07, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

May 05, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

March 26, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

March 19, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

March 17, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

March 16, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

March 10, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

March 03, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

These stocks have an unusual volume in today's session ↗

January 28, 2026

Via Chartmill

Tuesday's after hours session: top gainers and losers ↗

January 27, 2026

Via Chartmill

The market is filled with gapping stocks in Monday's session. ↗

January 26, 2026

Via Chartmill

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 18, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

December 02, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

November 17, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗

November 12, 2025

Via Chartmill

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

November 12, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Preview: Acumen Pharmaceuticals's Earnings ↗

November 11, 2025

Via Benzinga

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?

Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market

What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?

The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 2.700

When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 07/09/26 04:00 PM ET

What is the market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock is 109.35M

How many shares of Acumen Pharmaceuticals, Inc. - Common Stock are outstanding?

Acumen Pharmaceuticals, Inc. - Common Stock has 109M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.